CD95 and CD95L promote and protect cancer stem cells

被引:0
|
作者
Paolo Ceppi
Abbas Hadji
Frederick J. Kohlhapp
Abhinandan Pattanayak
Annika Hau
Xia Liu
Huiping Liu
Andrea E. Murmann
Marcus E. Peter
机构
[1] Feinberg School of Medicine,Division Hematology/Oncology
[2] Northwestern University,Department of Pathology and Case Comprehensive Cancer Center
[3] School of Medicine,undefined
[4] Case Western Reserve University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
CD95 (APO-1/Fas) is a death receptor used by immune cells to kill cancer cells through induction of apoptosis. However, the elimination of CD95 or its ligand, CD95L, from cancer cells results in death induced by CD95R/L elimination (DICE), a type of cell death that resembles a necrotic form of mitotic catastrophe suggesting that CD95 protects cancer cells from cell death. We now report that stimulation of CD95 on cancer cells or reducing miR-200c levels increases the number of cancer stem cells (CSCs), which are more sensitive to induction of DICE than non-CSC, while becoming less sensitive to CD95-mediated apoptosis. In contrast, induction of DICE or overexpression of miR-200c reduces the number of CSCs. We demonstrate that CSCs and non-CSCs have differential sensitivities to CD95-mediated apoptosis and DICE, and that killing of cancer cells can be maximized by concomitant induction of both cell death mechanisms.
引用
收藏
相关论文
共 50 条
  • [21] CD95/CD95L engagement is a requirement for stable embryonic stem cell engraftment in allogeneic recipients.
    Fabricius, D
    Bonde, S
    Zavazava, N
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 599 - 599
  • [22] Characterization of CD95 ligand (CD95L)-induced apoptosis in human tenon fibroblasts
    Hueber, A
    Welsandt, G
    Jordan, JF
    Mietz, H
    Weller, M
    Krieglstein, GK
    Esser, PJ
    EXPERIMENTAL EYE RESEARCH, 2002, 75 (01) : 1 - 8
  • [23] CD95L mRNA is toxic to cancer cells
    Putzbach, William
    Haluck-Kangas, Ashley
    Gao, Quan
    Sarshad, Aishe A.
    Bartom, Elizabeth
    Stults, Austin
    Qadir, Abdul S.
    Scholtens, Denise M.
    Hafner, Markus
    Peter, Marcus
    CANCER RESEARCH, 2018, 78 (13)
  • [24] The role of CD95 and CD95 ligand in cancer
    M E Peter
    A Hadji
    A E Murmann
    S Brockway
    W Putzbach
    A Pattanayak
    P Ceppi
    Cell Death & Differentiation, 2015, 22 : 549 - 559
  • [25] Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L
    Sigel, JE
    Hsi, ED
    MODERN PATHOLOGY, 2000, 13 (04) : 446 - 451
  • [26] The role of CD95 and CD95 ligand in cancer
    Peter, M. E.
    Hadji, A.
    Murmann, A. E.
    Brockway, S.
    Putzbach, W.
    Pattanayak, A.
    Ceppi, P.
    CELL DEATH AND DIFFERENTIATION, 2015, 22 (04): : 549 - 559
  • [27] Survival and immunosuppressive functions of myeloid-derived suppressor cells are not regulated by the CD95/CD95L system
    Blossey, R. D. S.
    Messmann, J. J.
    Debatin, K. M.
    Strauss, G.
    IMMUNOLOGY, 2012, 137 : 425 - 425
  • [28] CD95L/CD95 GENE DELETION DECREASES MOUSE GLIOMA TUMORIGENESIS THROUGH THE INHIBITION OF NON-CANONICAL CD95L/CD95-MEDIATED CELL GROWTH AND IMMUNOSUPPRESSION
    Quijano-Rubio, Clara
    Weller, Michael
    NEURO-ONCOLOGY, 2021, 23 : 37 - 38
  • [29] Carboxy-terminal domain of CD95 suppresses anti-CD95 antibody mediated but not CD95L mediated
    Thilenius, ARB
    Russell, JH
    FASEB JOURNAL, 1996, 10 (06): : 408 - 408
  • [30] CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract:: fictions and facts
    Sträter, J
    Möller, P
    VIRCHOWS ARCHIV, 2003, 442 (03) : 218 - 225